Md. Ali Mujtaba

Dr. Md. Ali Mujtaba

Pharmaceutics department, Faculty of pharmacy, Northern Border University, Arar, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
Shadab MDShadab MD
Shadab MD
SBSubrat K. Bhattmisra
Subrat K. Bhattmisra
FZFarrukh Zeeshan
Farrukh Zeeshan
NSNaiyer Shahzad
Naiyer Shahzad
MMMd. Ali Mujtaba
Md. Ali Mujtaba
JAJaved Ali
Javed Ali

22 August 2017 in Artificial Cells, Nanomedicine, and Biotechnology
Verified
Journal Article
Closed access
MAMd Habban Akhter
Md Habban Akhter
RIRizwanullah
Rizwanullah
Javed AhmadJaved Ahmad
Javed Ahmad
MOHAMED JAWED AHSANMOHAMED JAWED AHSAN
MOHAMED JAWED AHSAN
MMMd. Ali Mujtaba
Md. Ali Mujtaba
SASaima Amin
Saima Amin
Cancer has been growing nowadays consequently high number of death ascertained worldwide. The medical intervention involves chemotherapy, radiation therapy and surgical removal. This conventional technique lacking targeting potential and harm the normal cells. In drug treatment regimen, the combination therapy is preferred than single drug treatment module due to higher internalization of chemotherapeutics in the cancer cells both by enhance permeation retention effect and by direct cell apoptosis. The cancer therapeutics involves different methodologies of delivering active moiety to the target site. The active and passive transport mode of chemotherapeutic targeting utilizes advance nanocarriers. The nanotechnological strategic treatment applying advance nanocarrier greatly helps in mitigating the cancer prevalence. The nanocarrier-incorporating nanodrug directed for specific area appealed scientist across the globe and issues to be addressed in this regard. Therefore, various techniques and approaches invented to meet the objectives. With the advances in nanomedicine and drug delivery, this review briefly focused on various modes of nanodrug delivery including nanoparticles, liposomes, dendrimer, quantum dots, carbon nanotubes, metallic nanoparticles, nanolipid carrier (NLC), gold nanoshell, nanosize cantilevers and nanowire that looks promising and generates a novel horizon in cancer therapeutics.

18 December 2019 in Journal of Microencapsulation
Verified
Journal Article
Closed access
KSKriti Soni
Kriti Soni
MMMd. Ali Mujtaba
Md. Ali Mujtaba
MAMd Habban Akhter
Md Habban Akhter
AZAmeeduzzafar Zafar
Ameeduzzafar Zafar
KKKanchan Kohli
Kanchan Kohli
Aim: The optimization and evaluation of ethosomal nanogel (NGs) for topical delivery in skin cancer. Methods: The formulations were optimized by employing 3-factor, 3-level Box Behnken design for responses of vesicle size, and fluxes. They characterized in vitro and evaluated for drug release, permeation and retention, skin penetration of ethosome, electron microscopy, texture analysis, and in vitro cytotoxicity. Results: The optimized formulation exhibited z-average 125.67 ± 10.43 nm, apparent zeta potential -17.1 ± 2.61 mV, average flux of drug loaded ethosome were 54.72 ± 5.45 and 59.83 ± 6.09 µg/cm2/h. Further, Rhodamine B loaded ethosome penetrated deeper up to 183.82 µm. The NGs texture analysis showed index of viscosity 225.45 g.s, firmness 209.34 g, cohesiveness -189.48 g, and consistency 59.45 g.s. The optimized ethosome NGs exhibited significant anti-cancer effect in B16-F10 murine tumor cell line (p < 0.05). Conclusion: Ethosomal NGs could be promising for skin cancer treatment.

6 January 2020 in Journal of Pharmaceutical Innovation
Verified
Journal Article
Closed access
PDF file
Ameeduzzafar zafarAmeeduzzafar zafar
Ameeduzzafar zafar
MQMohd Qumber
Mohd Qumber
Nabil AlruwailiNabil Alruwaili
Nabil Alruwaili
SBSyed Nasir Abbas Bukhari
Syed Nasir Abbas Bukhari
KAKhalid Saad Alharbi
Khalid Saad Alharbi
AAAsgar Ali
Asgar Ali

1 January 2014 in Chemical Engineering Research and Design
Verified
Journal Article
Closed access
MMMd. Ali Mujtaba
Md. Ali Mujtaba
MAMushir Ali
Mushir Ali
KKKanchan Kohli
Kanchan Kohli

1 January 2022 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
MMMd. Ali Mujtaba
Md. Ali Mujtaba
MAMd Habban Akhter
Md Habban Akhter
SASarfaraz Alam
Sarfaraz Alam
MAMohammad Daud Ali
Mohammad Daud Ali
AHAfzal Hussain
Afzal Hussain
Natural products are well known for their high potency with minimum side effects. Plant extracts are the most commonly used natural products because of their ease of availability and relatively low production cost. Berberine (BBR), a phytochemical component of some Chinese medicinal herbs (most commonly Berberis vulgaris), is an isoquinoline alkaloid with several biological and pharmacological effects including antioxidant, anti-inflammatory, antitumour, antimicrobial, antidepressant, hepatoprotective, hypolipidemic, and hypoglycemic actions. Interestingly, multiple studies have shown that BBR is a potential drug candidate with a multi-spectrum therapeutic application. However, the oral delivery of BBR is challenged owing to its poor bioavailability. Therefore, its oral bioavailability needs to be enhanced before it can be used in many clinical applications. This review provides an overview of the various studies that support the broad range of pharmacological activities of BBR. Also, it includes a section to address the issues and challenges related to the drug and methods to improve the properties of BBR, such as solubility, stability and bioavailability that may be explored to help patients reap the maximum benefit from this potentially useful drug.